Interferon beta-1a HSA-free biosimilar ( DrugBank: Interferon beta-1a, Interferon beta )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
13 | 多発性硬化症/視神経脊髄炎 | 1 |
13. 多発性硬化症/視神経脊髄炎
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02517788 (ClinicalTrials.gov) | May 2006 | 5/8/2015 | Phase I BP Interferon (IFN) Beta-004 | Comparative Pharmacokinetic Profile of Interferon Beta-1a (Bioferon®) Administered as Single i.v. Doses in HSA-free Formulation and HSA+ Solution and as Multiple s.c. Doses in Healthy Subjects | Multiple Sclerosis, Relapsing-Remitting | Drug: Interferon beta-1a HSA-free biosimilar;Drug: Interferon beta-1a HSA+ biosimilar;Drug: Interferon beta-1a original | Centre Hospitalier Universitaire Vaudois | BioPartners GmbH | Completed | 18 Years | 45 Years | Both | 24 | Phase 1 | NULL |